Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)
Taiwan
· Delayed Price · Currency is TWD 32.55
-0.55 (-1.66%)
Jun 5, 2025, 2:38 PM CST
Sinphar Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 3,179 | 3,151 | 2,963 | 2,857 | 2,434 | 2,388 | Upgrade
|
| Revenue Growth (YoY) | 7.06% | 6.33% | 3.72% | 17.39% | 1.89% | -0.26% | Upgrade
|
| Cost of Revenue | 1,912 | 1,910 | 1,869 | 1,764 | 1,545 | 1,513 | Upgrade
|
| Gross Profit | 1,267 | 1,240 | 1,094 | 1,093 | 888.71 | 875.53 | Upgrade
|
| Selling, General & Admin | 791.35 | 791.65 | 670.93 | 621.34 | 557.06 | 537.16 | Upgrade
|
| Research & Development | 140.66 | 151.36 | 132.58 | 272.16 | 511.88 | 462.4 | Upgrade
|
| Operating Expenses | 932.15 | 943.15 | 805.19 | 893.97 | 1,071 | 997.73 | Upgrade
|
| Operating Income | 335.1 | 297.16 | 288.74 | 198.63 | -182.77 | -122.2 | Upgrade
|
| Interest Expense | -36.87 | -36.77 | -33.71 | -27.81 | -24.8 | -24.51 | Upgrade
|
| Interest & Investment Income | 17.25 | 16.84 | 12.31 | 5.78 | 3.68 | 3.8 | Upgrade
|
| Currency Exchange Gain (Loss) | 13.43 | 13.43 | 3.79 | 21.31 | -6.96 | -12.61 | Upgrade
|
| Other Non Operating Income (Expenses) | 11.8 | 18.93 | 29.46 | 47.96 | 27.82 | 37.6 | Upgrade
|
| EBT Excluding Unusual Items | 340.7 | 309.58 | 300.58 | 245.86 | -183.03 | -117.92 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.48 | -2.48 | 5.13 | -0.81 | -1.5 | 0.14 | Upgrade
|
| Pretax Income | 338.22 | 307.1 | 305.71 | 245.05 | -184.53 | -117.77 | Upgrade
|
| Income Tax Expense | 48.75 | 21.88 | -51.07 | 80.87 | 20.43 | 54.79 | Upgrade
|
| Earnings From Continuing Operations | 289.47 | 285.22 | 356.78 | 164.17 | -204.96 | -172.56 | Upgrade
|
| Minority Interest in Earnings | 17.24 | 19.49 | 18.39 | 60.47 | 166.82 | 144.05 | Upgrade
|
| Net Income | 306.71 | 304.71 | 375.17 | 224.64 | -38.14 | -28.51 | Upgrade
|
| Net Income to Common | 306.71 | 304.71 | 375.17 | 224.64 | -38.14 | -28.51 | Upgrade
|
| Net Income Growth | -24.35% | -18.78% | 67.01% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 181 | 181 | 181 | 181 | 181 | 181 | Upgrade
|
| Shares Outstanding (Diluted) | 182 | 181 | 181 | 181 | 181 | 181 | Upgrade
|
| Shares Change (YoY) | 0.06% | 0.02% | -0.00% | 0.17% | - | -0.07% | Upgrade
|
| EPS (Basic) | 1.69 | 1.68 | 2.07 | 1.24 | -0.21 | -0.16 | Upgrade
|
| EPS (Diluted) | 1.69 | 1.68 | 2.07 | 1.24 | -0.21 | -0.16 | Upgrade
|
| EPS Growth | -24.25% | -18.84% | 66.91% | - | - | - | Upgrade
|
| Free Cash Flow | 427.1 | 353.08 | 0.86 | 283.82 | -10.64 | 2.38 | Upgrade
|
| Free Cash Flow Per Share | 2.35 | 1.95 | 0.01 | 1.56 | -0.06 | 0.01 | Upgrade
|
| Dividend Per Share | - | 1.000 | 0.926 | 0.926 | 0.185 | 0.185 | Upgrade
|
| Dividend Growth | - | 8.00% | - | 399.95% | - | - | Upgrade
|
| Gross Margin | 39.87% | 39.37% | 36.92% | 38.25% | 36.52% | 36.66% | Upgrade
|
| Operating Margin | 10.54% | 9.43% | 9.74% | 6.95% | -7.51% | -5.12% | Upgrade
|
| Profit Margin | 9.65% | 9.67% | 12.66% | 7.86% | -1.57% | -1.19% | Upgrade
|
| Free Cash Flow Margin | 13.44% | 11.21% | 0.03% | 9.93% | -0.44% | 0.10% | Upgrade
|
| EBITDA | 579.51 | 539.99 | 518.14 | 446.69 | 63.93 | 112.68 | Upgrade
|
| EBITDA Margin | 18.23% | 17.14% | 17.49% | 15.64% | 2.63% | 4.72% | Upgrade
|
| D&A For EBITDA | 244.41 | 242.83 | 229.4 | 248.06 | 246.7 | 234.88 | Upgrade
|
| EBIT | 335.1 | 297.16 | 288.74 | 198.63 | -182.77 | -122.2 | Upgrade
|
| EBIT Margin | 10.54% | 9.43% | 9.74% | 6.95% | -7.51% | -5.12% | Upgrade
|
| Effective Tax Rate | 14.41% | 7.13% | - | 33.00% | - | - | Upgrade
|
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.